• MRSA Detection : 6 Hours

  • Group B Strep Detection : ± 6 Hours

  • E. coli Detection : 4 Hours

  • Anthrax Detection : ± 1 Hour

RAPID DETECTION OF VIABLE MICROORGANISMS

NanoLogix® is a biotechnology company specializing in live cell, rapid diagnostics. Our kits are simple and reliable rapid test solutions that detect active threat bacteria and other microorganisms 4x - 12x faster than traditional Petri culture technology, and more cost effectively than PCR Protocol.

Stock Symbol: NNLX

Reuter's Report

NanoLogix featured in Reuters Television Global Business News

<more videos>

NanoLogix Clean Room

250-712-6314

Inside the NanoLogix Production Cleanroom

<more videos>

MRSA 4x Faster

Jonathan Faro MD, Ph.D at the University of Texas Health Science Center test results for MRSA

<more videos>

COMPANY OPERATIONS SUMMARY

April 30, 2013

Company Update

The past fifteen months have been highly successful for NanoLogix as it continues to develop new products and new markets. In that time, the company has advanced in a number of important areas, including development of new technologies, increasing sales and customer bases, and garnering substantial recognition in published research on NanoLogix products and techniques. We are excited by these developments and by additional new opportunities.

New Technologies

The technological developments at NanoLogix are revolutionary. Besides improving on existing BNP and BNF products and protocols, the Company has gained great success in the market for its Extended-Life Petri dishes and BNP diagnostic kits that are vacuum-packed in gas charged FlatPacks. The FlatPack technology – exclusively licensed by NanoLogix – represents a major breakthrough in supply-chain management for these products. Users of FlatPack-packaged Petri dishes can potentially achieve significant cost savings and supply chain efficiencies over traditional Petri dish supply because select-media FlatPack plates do not require refrigeration, have a significantly reduced rate of loss in shipment and storage, and have a shelf life far beyond that of traditional Petri dishes. The company is currently selling Extended-Life Petri dishes and BNP diagnostic kits that are vacuum-packed in gas-charged FlatPacks and made in various common nutrient media configurations. Customers to date include independent laboratories and hospital laboratories, defense contractors and Federal agencies. NanoLogix products are at present being used on six classified Federal government projects, with expanded use expected this year. Those projects are funded by the United States Department of Defense and the Environmental Protection Agency.

In the past year we and our collaborators in research and development have made significant refinements to our existing technologies and have also developed one additional rapid test. The new test has been named the N-Assay. The N-Assay is a unique ELISA multiwell machine-readable assay that provides results for bacteria identification and antibiotic sensitivity in less than one hour with high sensitivity and specificity. Indications to date are that the N-Assay will provide rapid results for any bacteria for which an antibody exists. We at NanoLogix and the researchers using the N-Assay are very excited at this new development. The N-Assay is projected to provide a premier platform for Point-of–Care rapid diagnostics. N-Assay patent filings were made in 2013. It is projected that the N-Assay will be more suitable for use in some developed areas than our BNF identification technology, but not in other areas or regions that are less developed.

Scholarship and Research on NanoLogix Technologies

In December 2012 a paper was published in the Journal of Microbial and BioChemical Technology detailing preliminary results using the company’s BNP technology for detection of live Tuberculosis through culture. Those results were obtained in five days, compared to weeks with standard culture methods. /www.omicsonline.org/1948-5948/pdfdownload.php?download=JMBT-04-147.pdf In January of 2013 the final results of a 356 patient clinical study by researchers at the University of Texas Health Science Center at Houston were published in the Journal of Infectious Diseases in Obstetrics and Gynecology detailing the results obtained with NanoLogix’s BNF technology for rapid detection of Group B Streptococcus in pregnant patients. /www.hindawi.com/journals/idog/2013/367935/

New License and Patents

The company has been recently granted a patent for its BNP technology in Japan, its BNC technology in China, and has indications that it will soon receive a grant of patent in the EU for BNP. Patents are pending for BNP in the US, China, Russia, India, Brazil and the EU. Patents for BNF technology are pending in the US, China, the EU, Japan, India and Brazil. A US patent was granted in April 2013 for the FlatPack packaging technology, to which NanoLogix has an exclusive license. The FlatPack technology has been pivotal to the sales of filled Petri plates by the company, with extraordinary increases in shelf life, durability of product during shipping, and numerous other advantages over all competitors’ similar products. We have exhibited our BNF and BNP and licensed FlatPack Petri technologies at multiple events: the American Society for Microbiology (ASM) BioDefense and Emerging Diseases Meeting and the Food Safety Summit, both in Washington, D.C., and at the ASM Annual Meeting in San Francisco

Marketing

In 2013, NanoLogix contracted with a team of independent marketing specialists to promote the Company’s products to key opinion leaders (KOLs) and executives in multiple health, industrial, pharmaceutical and food sectors. The marketing team is composed of current or former directors and managers of two national and international pharmaceutical corporations. This alliance continues the transition of the Company from a primary focus on research and development to one of production and marketing. There will be a continued science emphasis upon product Quality Assurance and Quality Control and also water quality test development with the US EPA. This new focus is resulting in a reallocation of resources with a heavy emphasis upon increased high level marketing on multiple fronts.

Financial Matters

As of 1 April 2013, the company has 122,679,679 shares outstanding of an authorized limit of 200,000,000 shares. Our current monthly operations costs are approximately $42,000.  That amount includes the costs of NanoLogix-funded studies, other tests of our products by third parties, and new patent applications. NanoLogix is funded by a combination of revenue from increasing sales, loans to the company by its CEO, and a limited number of private placement stock sales, with investors providing funding in exchange for common stock restricted from market sale for one year from date of issuance. The company does not sell shares on the open market. The Company has received a number of inquiries regarding share compensation to Directors and sales of those shares. All Directors are compensated for their contribution to the Company by payment in restricted shares. The Directors are closely involved with the business of the Company, communicate with the CEO on a daily or near-daily basis, and participate in board of director meetings regularly. All Directors have been personally involved in assisting financially with the needs of the Company, both through personal direct investment and also through facilitation of private placement investment from friends, family, colleagues, and associates who approached the Directors. The Directors have been responsible in this way for the overwhelming majority of funds raised to run the company over the past five years, amounting to roughly 92% of funds raised. To date, none of the shares paid to the Directors, including the CEO, have been sold. All of the share certificates issued to the members of the Board of Directors are still classed as restricted shares and can only be sold under strict SEC Rule 144 guidelines. In summation, there has been no realized monetary gain from the shares received as compensation by the Board of Directors --- the shares cannot be used as collateral for loans, nor can they be classed as a liquid asset. The Board of Directors is independent, with the directors employed individually in professions completely unrelated to the business of NanoLogix. Their work as Directors of the Company has been based upon what they believe to be the potential of the Company, not for any immediate capital gain.

In late 2012 and early 2013 Nanologix was approached separately by two multibillion dollar corporations regarding business association, development and product usage. NanoLogix has signed Mutual Confidentiality Agreements with both corporations.

NANOLOGIX® NEWS

06.21.13 NanoLogix BNP Instructional Video







06.11.13 02:31 Nanologix® News: US EPA and NanoLogix to Extend Agreement to 2015 805-306-9834

NanoLogix Clean Room

04.30.13 06:00 nologix® News: NanoLogix to Exhibit at Food Safety Summit in Baltimore and American Society for Microbiology Annual Meeting in Denver. Read more>>>

04.02.13 10:29 Nanologix® News:NanoLogix has been informed that they have been granted a patent in Japan for the Company's BNP detection technology. This is the first granted patent of seven patents pending for BNP throughout the world..

03.13.13 10:29 Nanologix® News:UTHealth researchers say more rapid test for Group B strep successful. 877-283-6269

02.20.13 10:29 Nanologix® News: NanoLogix Bacteria Detection Plates Break Longevity Records Using Anthrax as Reference Bacteria. Read more>>>

01.11.13 16:29 Nanologix® News: nanologix packing systemThird-party results for ongoing agar room temperature (RT) testing at 4 months+. Current NanoLogix internal lab results for RT testing have passed the 9-month point, with no degradation of the agar. Read more>>>

12.17.12 Nanologix® News: The results of a study for rapid TB detection and identification by a major third-party research facility utilizing NanoLogix BioNanoPore (BNP) technology have been published in the Journal of Microbial & Biochemical Technology. The study demonstrates the potential of NanoLogix BNP to detect live TB in a fraction of the time required by traditional methods. Study results with BNP show five-day detection of live TB vs 19 days with non-BNP technology. 256-787-3413

11.13.12 Nanologix® News: US Environmental Protection Agency Issues Featured News Article Covering Cooperation With NanoLogix. Read more>>

11.09.12 Nanologix® News: NanoLogix Subject of EPA Featured News article. 947-823-3616

10.21.12 Nanologix® News: NanoLogix is pleased to welcome Giles Manley, MD to its Science Advisory Board. Read more>>

8.21.12 The Vindicator: NanoLogix to begin selling products Read more>>

8.21.12
Device Space: NanoLogix, Inc. (NNLX) Rapid Diagnostic Technologies Set to Enter Market Under FDA 510K-Exempt Status (301) 926-3902

7.16.12 BioProcessing Journal: Advanced Culture Method Ends the Wait for Viable Microbial Detection 772-934-8299 Global BioDefense: NanoLogix Improves Live-Cell Detection Times for Biothreat Agents Read more>>

6.13.12 Health News Texas: Texas Health Science Center-Huston instrumental in New NanoLogix Technology Read the article>>

SIGN UP FOR eNEWS

COMPANY UPDATES

  • August 18, 2013:
    Dr Jonathan Faro of the UTHSC at Houston presented two posters at the IDSOG meeting in Albuquerque showing the results of tests with NanoLogix BNF and new Multiwell N-Assay diagnostics. The N-Assay delivered 30 minute results for detection and identification of Group B Streptococcus (GBS) while the BNF provided detection, identification, and determination of sensitivity to clindamycin antibiotic in 6 - 6.5 hours. Both tests are significantly faster than the standard tests in use, which take 48-72 hours for the same results. The significance of the results and impact upon screening for GBS in pregnancies, and potentially in the elderly and immuno-compromised patients of all ages, is tremendous.

    7344988561
    2. Clinda.pdf
  • August 06, 2013:
    NanoLogix Inc. Report on technologies

    To assist in the commercialization, production, and marketing of NanoLogix BNP, N-Assay, BNF, and..
  • April 05, 2013:
    NanoLogix plans to begin marketing this summer of their new N-Assay Multiwell Diagnostic test. The N-Assay is a machine-readable test that will be available in an assortment of size configurations for detection and identification of a variety of bacteria. Tests to date have provided consistent results in as little as 30 minutes with both high sensitivity and specificity.

  • April 02, 2013:
    NanoLogix has been informed that they have been granted a patent in Japan for the Company's BNP detection technology. This is the first granted patent of seven patents pending for BNP throughout the world.